ticker,event_date,window_start,window_end,symbol,symbols,publishedDate,publishedDateET,date_et,title,text,site,url,image
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-10 07:00:00,2024-07-10T07:00:00-04:00,2024-07-10,3 Undervalued Stocks Set to Outperform the Market in 2024,"During stock investing, having a list of the top undervalued stocks can offer lucrative opportunities for value growth and portfolio stability. Here are three stocks whose intrinsic value exceeds their current market price, promising potential gains as the market corrects itself.",investorplace.com,https://investorplace.com/2024/07/3-undervalued-stocks-set-to-outperform-the-market-in-2024/,https://images.financialmodelingprep.com/news/3-undervalued-stocks-set-to-outperform-the-market-in-20240710.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-10 17:23:49,2024-07-10T17:23:49-04:00,2024-07-10,"53 July Dividend Kings: Buy 8, Watch 8 More","""What is a Dividend King? A stock with 50 or more consecutive years of dividend increases.""—suredividend.com. The 53 Dividend Kings, screened as of July 8, represented 8 of 11 Morningstar Sectors. Broker-targeted top-ten net-gains ranged 18.24%-30.31% topped-by Kenvue, and Genuine Parts. By yield, Altria tops-all. Top-ten July listings: SWK, FRT, KVUE, FTS, UBSI, BKH, NWN, CDUAF, UVV, MMM, & MO averaged 5.37% in yield.",seekingalpha.com,https://seekingalpha.com/article/4703413-53-july-dividend-kings-buy-8-watch-8-more,https://images.financialmodelingprep.com/news/53-july-dividend-kings-buy-8-watch-8-more-20240710.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-11 04:51:00,2024-07-11T04:51:00-04:00,2024-07-11,3 Magnificent Dow Stocks That Are No-Brainer Buys for the Second Half of 2024,"The Dow has served as the top barometer of Wall Street's health for well over a century. Though the Dow Jones Industrial Average is predominantly comprised of mature businesses, most are well-positioned to make their shareholders richer over the long run.",fool.com,https://www.fool.com/investing/2024/07/11/3-dow-stocks-no-brainer-buys-for-second-half-2024/,https://images.financialmodelingprep.com/news/3-magnificent-dow-stocks-that-are-nobrainer-buys-for-20240711.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-11 08:40:40,2024-07-11T08:40:40-04:00,2024-07-11,Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality,"Johnson & Johnson will announce its Q2 2024 results on Wednesday, July 17 before the market opens. In this update, I share what to expect from JNJ's Q2 results and put previous results into perspective. In the main part of the article, I will take a close look at JNJ's earnings adjustments, amid the significant deviation from GAAP earnings (+46% median since 2014).",seekingalpha.com,https://seekingalpha.com/article/4703489-johnson-and-johnson-q2-earnings-preview-scrutinizing-its-earnings-quality,https://images.financialmodelingprep.com/news/johnson-johnson-q2-earnings-preview-scrutinizing-its-earnings-quality-20240711.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-12 06:23:00,2024-07-12T06:23:00-04:00,2024-07-12,3 Essential Stocks for Building a Recession-Proof Portfolio,Recession-proof stocks offer investors a safe harbor to shield their portfolios from downside risk. The stock market has cooled off following its AI-powered surge for the last two years.,investorplace.com,https://investorplace.com/2024/07/3-essential-stocks-for-building-a-recession-proof-portfolio/,https://images.financialmodelingprep.com/news/3-essential-stocks-for-building-a-recessionproof-portfolio-20240712.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-12 10:21:05,2024-07-12T10:21:05-04:00,2024-07-12,Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics,"Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.",zacks.com,https://www.zacks.com/stock/news/2300663/unlocking-q2-potential-of-johnson-johnson-jnj-exploring-wall-street-estimates-for-key-metrics?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm_preview-2300663,https://images.financialmodelingprep.com/news/unlocking-q2-potential-of-johnson-johnson-jnj-exploring-wall-20240712.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-12 15:22:45,2024-07-12T15:22:45-04:00,2024-07-12,A 15-Stock Dividend Growth Retirement Portfolio For Stagflation,We discuss why our base case for the U.S. economy is stagflation. We share a 15-stock portfolio that is well-positioned for a stagflationary environment. We share why it is positioned to deliver an attractive current dividend yield along with strong dividend growth.,seekingalpha.com,https://seekingalpha.com/article/4703785-a-15-stock-dividend-growth-retirement-portfolio-for-stagflation,https://images.financialmodelingprep.com/news/a-15stock-dividend-growth-retirement-portfolio-for-stagflation-20240712.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-12 20:15:40,2024-07-12T20:15:40-04:00,2024-07-12,3 Key Earnings Reports to Watch Next Week,"With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including these three.",zacks.com,https://www.zacks.com/stock/news/2301247/3-key-earnings-reports-to-watch-next-week?cid=CS-STOCKNEWSAPI-FT-stocks_in_the_news-2301247,https://images.financialmodelingprep.com/news/3-key-earnings-reports-to-watch-next-week-20240712.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-14 04:27:00,2024-07-14T04:27:00-04:00,2024-07-14,3 High-Yield Dividend Stocks That Still Look Like Bargains,Johnson & Johnson and AbbVie produce reliable earnings driven by sales of patent-protected drugs. Real estate investment trust Agree Realty makes monthly dividend payments.,fool.com,https://www.fool.com/investing/2024/07/14/3-high-yield-dividend-stocks-that-still-look-like/,https://images.financialmodelingprep.com/news/3-highyield-dividend-stocks-that-still-look-like-bargains-20240714.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-14 09:31:00,2024-07-14T09:31:00-04:00,2024-07-14,2 Healthcare Stocks to Buy Hand Over Fist This Month,"Johnson & Johnson and Medtronic are healthcare leaders that have faced their share of issues in recent years. Still, both companies have the innovative capabilities and expertise to succeed in the industry in the long run.",fool.com,https://www.fool.com/investing/2024/07/14/2-healthcare-stocks-to-buy-hand-over-fist-this-mon/,https://images.financialmodelingprep.com/news/2-healthcare-stocks-to-buy-hand-over-fist-this-20240714.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-15 06:38:00,2024-07-15T06:38:00-04:00,2024-07-15,Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever,Litigation concerns have pushed Johnson & Johnson to an appealing price. Dividend investors will love AbbVie's high yield and resilient growth.,fool.com,https://www.fool.com/investing/2024/07/15/want-decades-of-passive-income-3-stocks-to-buy-now/,https://images.financialmodelingprep.com/news/want-decades-of-passive-income-3-stocks-to-buy-20240715.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-15 11:50:39,2024-07-15T11:50:39-04:00,2024-07-15,J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?,J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.,zacks.com,https://www.zacks.com/stock/news/2301766/j-j-jnj-stock-before-q2-earnings-to-buy-or-not-to-buy?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2301766,https://images.financialmodelingprep.com/news/jj-jnj-stock-before-q2-earnings-to-buy-or-20240715.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-16 06:15:00,2024-07-16T06:15:00-04:00,2024-07-16,"If You Can Only Buy One Dow Stock in July, It Better Be One of These 3 Names",Finding Dow stocks to buy is often seen as a conservative yet effective strategy for those looking to secure stable returns with minimal risk. The Dow Jones Industrial Average comprises companies from a wide array of industries.,investorplace.com,https://investorplace.com/2024/07/if-you-can-only-buy-one-dow-stock-in-july-it-better-be-one-of-these-3-names/,https://images.financialmodelingprep.com/news/if-you-can-only-buy-one-dow-stock-in-20240716.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-16 07:00:00,2024-07-16T07:00:00-04:00,2024-07-16,MedTech To Drive Johnson & Johnson's Q2?,"Johnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively.",forbes.com,https://www.forbes.com/sites/greatspeculations/2024/07/16/medtech-to-drive-johnson--johnsons-q2/,https://images.financialmodelingprep.com/news/medtech-to-drive-johnson-johnsons-q2-20240716.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-16 08:06:35,2024-07-16T08:06:35-04:00,2024-07-16,How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings,"Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.",benzinga.com,https://www.benzinga.com/news/earnings/24/07/39790748/how-to-earn-500-a-month-from-johnson-johnson-stock-ahead-of-q2-earnings,https://images.financialmodelingprep.com/news/how-to-earn-500-a-month-from-johnson-johnson-20240716.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-16 12:46:16,2024-07-16T12:46:16-04:00,2024-07-16,Johnson & Johnson: Bullish Charts Signal Strong Setup Before Q2 Earnings,Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.,benzinga.com,https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39799990/johnson-johnson-bullish-charts-signal-strong-setup-before-q2-earnings,https://images.financialmodelingprep.com/news/johnson-johnson-bullish-charts-signal-strong-setup-before-q2-20240716.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-16 15:04:01,2024-07-16T15:04:01-04:00,2024-07-16,3 Safe Dividend Kings to Recession-Proof Your Portfolio,"Income investors should focus on stocks that pay solid yields, but also those that have sustainable payouts and strong business models. Dividend kings are an excellent place to look for stocks with sustainable dividends.",investorplace.com,https://investorplace.com/2024/07/3-safe-dividend-kings-to-recession-proof-your-portfolio/,https://images.financialmodelingprep.com/news/3-safe-dividend-kings-to-recessionproof-your-portfolio-20240716.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-16 16:00:00,2024-07-16T16:00:00-04:00,2024-07-16,Johnson & Johnson Earnings Are Coming. It Took Steps to Put Its Talc Issues Behind It.,"ohnson & Johnson is expected to report earnings of $2.71 a share, down slightly from $2.80 from the same period a year ago.",barrons.com,https://www.barrons.com/articles/johnson-johnson-earnings-stock-price-3bddce00,https://images.financialmodelingprep.com/news/johnson-johnson-earnings-are-coming-it-took-steps-to-20240716.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 06:22:36,2024-07-17T06:22:36-04:00,2024-07-17,J&J beats Wall Street estimates on strong drug sales,"Johnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer treatment Darzalex and blockbuster psoriasis drug Stelara.",reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/jj-beats-wall-street-estimates-strong-drug-sales-2024-07-17/,https://images.financialmodelingprep.com/news/jj-beats-wall-street-estimates-on-strong-drug-sales-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 06:34:00,2024-07-17T06:34:00-04:00,2024-07-17,"Johnson & Johnson stock gets a lift from earnings beat, while outlook was mixed","Shares of Johnson & Johnson JNJ, +1.19% rose 1.1% in premarket trading Wednesday, after the drug maker beat second-quarter profit and sales expectations, while providing a mixed full-year outlook. Net income fell to $4.69 billion, or $1.93 a share, from $5.14 billion, or $2.05 a share, in the same period a year ago.",marketwatch.com,https://www.marketwatch.com/story/johnson-johnson-stock-gets-a-lift-from-earnings-beat-while-outlook-was-mixed-f6ceea5c,https://images.financialmodelingprep.com/news/johnson-johnson-stock-gets-a-lift-from-earnings-beat-while-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 07:05:00,2024-07-17T07:05:00-04:00,2024-07-17,3 Dividend Stocks With 3%+ Yields to Upgrade Your Annual Income,"If you are a passive income investor like me, you will always be on the lookout for high-yield dividend stocks. However, not all stocks are made equal.",investorplace.com,https://investorplace.com/2024/07/3-dividend-stocks-with-3-yields-to-upgrade-your-annual-income/,https://images.financialmodelingprep.com/news/3-dividend-stocks-with-3-yields-to-upgrade-your-annual-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 08:14:27,2024-07-17T08:14:27-04:00,2024-07-17,"Johnson & Johnson's Q2 Earnings: Revenue And Profit Beat On Strong Pharma Sales, Annual Profit Outlook Lowered On M&A Costs","On Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% year-over-year, beating the consensus of $2.70.",benzinga.com,https://www.benzinga.com/general/biotech/24/07/39813647/johnson-johnsons-q2-earnings-revenue-and-profit-beat-on-strong-pharma-sales-annual-profit-outlook,https://images.financialmodelingprep.com/news/johnson-johnsons-q2-earnings-revenue-and-profit-beat-on-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 08:30:17,2024-07-17T08:30:17-04:00,2024-07-17,Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates,"Johnson & Johnson (JNJ) came out with quarterly earnings of $2.82 per share, beating the Zacks Consensus Estimate of $2.71 per share. This compares to earnings of $2.80 per share a year ago.",zacks.com,https://www.zacks.com/stock/news/2303130/johnson-johnson-jnj-beats-q2-earnings-and-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_4-2303130,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-beats-q2-earnings-and-revenue-estimates-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 09:46:18,2024-07-17T09:46:18-04:00,2024-07-17,"Johnson & Johnson Posts Mixed Earnings, Shifts Full-Year Guidance","Johnson & Johnson (JNJ) reported mixed second-quarter results Wednesday, as one-time costs caused the company to miss profit estimates despite better-than-expected sales.",investopedia.com,https://www.investopedia.com/johnson-and-johnson-posts-mixed-earnings-shifts-full-year-guidance-8679181,https://images.financialmodelingprep.com/news/johnson-johnson-posts-mixed-earnings-shifts-fullyear-guidance-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 10:31:41,2024-07-17T10:31:41-04:00,2024-07-17,Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say,"While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.",zacks.com,https://www.zacks.com/stock/news/2303317/johnson-johnson-jnj-reports-q2-earnings-what-key-metrics-have-to-say?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|nfm-2303317,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-reports-q2-earnings-what-key-metrics-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 10:52:27,2024-07-17T10:52:27-04:00,2024-07-17,This Medical Giant's Stock Rebounds: A 15% Upside Is the Minimum,Johnson & Johnson NYSE: JNJ has struggled for the last year or two as the impacts of COVID-19 and the spin-off of Kenvue NYSE: KVUE work their way through the system. The takeaway from the Q2 earnings release is that organic growth is back in the picture.,marketbeat.com,https://www.marketbeat.com/stock-ideas/this-medical-giants-stock-rebounds-a-15-upside-is-the-minimum/,https://images.financialmodelingprep.com/news/this-medical-giants-stock-rebounds-a-15-upside-is-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 11:44:02,2024-07-17T11:44:02-04:00,2024-07-17,Johnson & Johnson climbs after earnings and revenue beat,"Johnson & Johnson (NYSE:JNJ) shares climbed 3% after second-quarter earnings fell less than expected.  Helped by 8% sales from its pharmaceutical arm, group revenue rose 4.3% to $22.45 billion, which was above the $22.3 billion Wall Street average forecast.",proactiveinvestors.com,https://www.proactiveinvestors.com/companies/news/1052139,https://images.financialmodelingprep.com/news/johnson-johnson-climbs-after-earnings-and-revenue-beat-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 12:17:10,2024-07-17T12:17:10-04:00,2024-07-17,Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript,"Johnson & Johnson (NYSE:JNJ ) Q2 2024 Earnings Conference Call July 17, 2024 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joe Wolk - Executive Vice President, Chief Financial Officer Joaquin Duato - Chairman and Chief Executive Officer Jennifer Taubert - Executive Vice President, Worldwide Chairman, Pharmaceuticals Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech John Reed - Executive Vice President, Innovative Medicine, R&D Conference Call Participants Chris Schott - JPMorgan Larry Biegelsen - Wells Fargo Louise Chen - Cantor Fitzgerald Rick Wise - Stifel Terence Flynn - Morgan Stanley Josh Jennings - TD Cowen Dave Risinger - Leerink Partners Danielle Antalffy - UBS Chris Shibutani - Goldman Sachs Joanne Wuensch - Citibank Operator Good morning, and welcome to Johnson & Johnson's Second Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session of the conference.",seekingalpha.com,https://seekingalpha.com/article/4704612-johnson-and-johnson-jnj-q2-2024-earnings-call-transcript,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-q2-2024-earnings-call-transcript-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 12:21:27,2024-07-17T12:21:27-04:00,2024-07-17,Housing Starts Increased More Than Expected,"Pre-market futures are down this morning. This does not appear to be as a result of any releases ahead of the open, but as sort of a mass realization that markets have climbed historically high over the past few weeks — even the Dow hit an all-time closing high yesterday — and another round of profit-taking seems to be in order.",zacks.com,https://www.zacks.com/stock/news/2303632/housing-starts-increased-more-than-expected?cid=CS-STOCKNEWSAPI-FT-economic_highlights-2303632,https://images.financialmodelingprep.com/news/housing-starts-increased-more-than-expected-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 12:30:44,2024-07-17T12:30:44-04:00,2024-07-17,"J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs",J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.,zacks.com,https://www.zacks.com/stock/news/2303646/j-j-jnj-q2-earnings-sales-top-eps-view-cut-on-m-a-costs?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2303646,https://images.financialmodelingprep.com/news/jj-jnj-q2-earnings-sales-top-eps-view-cut-on-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 13:04:18,2024-07-17T13:04:18-04:00,2024-07-17,5 Deep Value Stocks To Buy in July,"Warren Buffett champions value investing, focusing on undervalued companies with strong fundamentals for long-term growth and stability.",247wallst.com,https://247wallst.com/investing/2024/07/17/5-deep-value-stocks-to-buy-in-july/,https://images.financialmodelingprep.com/news/5-deep-value-stocks-to-buy-in-july-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 15:06:57,2024-07-17T15:06:57-04:00,2024-07-17,Johnson & Johnson Q2: Robust New Product Pipeline,"Johnson & Johnson beats market estimates for revenue and EPS in Q2 FY24. A strong product pipeline includes new drugs for ulcerative colitis and lung cancer. JNJ's acquisition of Shockwave Medical positions the company as a leader in the cardiovascular market, potential revenue synergies from integration.",seekingalpha.com,https://seekingalpha.com/article/4704640-johnson-and-johnson-q2-robust-new-product-pipeline,https://images.financialmodelingprep.com/news/johnson-johnson-q2-robust-new-product-pipeline-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 15:12:12,2024-07-17T15:12:12-04:00,2024-07-17,Stock Of The Day: Johnson & Johnson Hits Crucial Roadblock — Can It Break Through?,"Investors loved the Johnson & Johnson JNJ earnings report. The stock is trading much higher, but it has stalled out around an important resistance level.",benzinga.com,https://www.benzinga.com/trading-ideas/technicals/24/07/39824201/stock-of-the-day-johnson-johnson-hits-crucial-roadblock-can-it-break-through,https://images.financialmodelingprep.com/news/stock-of-the-day-johnson-johnson-hits-crucial-roadblock-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 17:39:20,2024-07-17T17:39:20-04:00,2024-07-17,"J&J MedTech Navigates Headwinds, Eyes Growth Surge in Second Half of 2024","Johnson & Johnson's (J&J) MedTech arm displayed resilience in its second quarter, navigating inflationary headwinds while prioritizing innovation. The unit, a key driver for J&J, remains committed to full-year growth targets despite temporary setbacks in its vision care business.",pymnts.com,https://www.pymnts.com/healthcare/2024/jj-medtech-navigates-headwinds-eyes-growth-surge-in-second-half-of-2024/,https://images.financialmodelingprep.com/news/jj-medtech-navigates-headwinds-eyes-growth-surge-in-second-half-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-17 18:14:00,2024-07-17T18:14:00-04:00,2024-07-17,Why Johnson & Johnson Stock Was a Winner on Wednesday,The healthcare sector mainstay unveiled its latest set of quarterly results. Its second-quarter headline figures comfortably beat the consensus-analyst estimates.,fool.com,https://www.fool.com/investing/2024/07/17/why-johnson-johnson-stock-was-a-winner-on-wednesda/,https://images.financialmodelingprep.com/news/why-johnson-johnson-stock-was-a-winner-on-wednesday-20240717.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-18 04:25:00,2024-07-18T04:25:00-04:00,2024-07-18,2 Magnificent S&P 500 Dividend Stocks Down 19% and 41% to Buy and Hold Forever,"Starbucks is experiencing weak sales this year, but it has plenty of opportunities to keep growing over the long term. Johnson & Johnson's focus on allocating capital to high-return opportunities has driven a 60-plus year track record of dividend growth.",fool.com,https://www.fool.com/investing/2024/07/18/2-sp-500-dividend-stocks-down-buy-forever/,https://images.financialmodelingprep.com/news/2-magnificent-sp-500-dividend-stocks-down-19-and-20240718.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-18 05:40:00,2024-07-18T05:40:00-04:00,2024-07-18,Is Johnson & Johnson a Buy Now?,"Johnson & Johnson reported results from the second quarter of 2024 on Wednesday, July 17. U.S. pharmaceutical sales grew by nearly 9% year over year in the second quarter.",fool.com,https://www.fool.com/investing/2024/07/18/is-johnson-johnson-a-buy-now/,https://images.financialmodelingprep.com/news/is-johnson-johnson-a-buy-now-20240718.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-18 12:12:40,2024-07-18T12:12:40-04:00,2024-07-18,These Analysts Revise Their Forecasts On Johnson & Johnson After Q2 Results,Johnson & Johnson JNJ reported better-than-expected second-quarter earnings on Wednesday.,benzinga.com,https://www.benzinga.com/news/earnings/24/07/39843593/these-analysts-revise-their-forecasts-on-johnson-johnson-after-q2-results,https://images.financialmodelingprep.com/news/these-analysts-revise-their-forecasts-on-johnson-johnson-after-q2-20240718.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-18 14:09:15,2024-07-18T14:09:15-04:00,2024-07-18,3 Dividend Stocks That Demand Investor Attention,"Dividend stocks pay dividends to their shareholders, representing a portion of the company's profits. Not all companies offer dividends.",investorplace.com,https://investorplace.com/2024/07/3-dividend-stocks-that-demand-investor-attention/,https://images.financialmodelingprep.com/news/3-dividend-stocks-that-demand-investor-attention-20240718.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-18 14:51:35,2024-07-18T14:51:35-04:00,2024-07-18,"Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst","Wednesday, Johnson & Johnson JNJ reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.",benzinga.com,https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39846742/johnson-johnson-prioritizes-sustainable-growth-in-m-a-amid-sector-diversification-s,https://images.financialmodelingprep.com/news/johnson-johnson-prioritizes-sustainable-growth-in-ma-amid-sector-20240718.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-19 07:00:00,2024-07-19T07:00:00-04:00,2024-07-19,Don't Overthink It - Bet On Safety And Predictability,"Howard Marks discusses the impact of debt on survival during economic challenges. Debt amplifies movements in investments and businesses, leading to potential survival challenges during economic downturns. Johnson & Johnson, Chevron, and Prologis are strong investment options with solid credit ratings and reliable business models.",seekingalpha.com,https://seekingalpha.com/article/4704876-dont-overthink-it-bet-on-safety-and-predictability,https://images.financialmodelingprep.com/news/dont-overthink-it-bet-on-safety-and-predictability-20240719.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-19 16:45:00,2024-07-19T16:45:00-04:00,2024-07-19,3 Blue-Chip Stocks to Buy for Christmas in July,"The Dow Jones Industrial Index is made up of 30 of the largest, publicly traded companies trading on either the New York Stock Exchange (NYSE) or the Nasdaq. These companies are known as blue-chip stocks to buy for their ability to deliver stable, reliable performance no matter what's going on in the economy.",investorplace.com,https://investorplace.com/2024/07/blue-chip-stocks-to-buy-3-names-offering-a-gift-to-investors/,https://images.financialmodelingprep.com/news/3-bluechip-stocks-to-buy-for-christmas-in-july-20240719.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-22 08:00:00,2024-07-22T08:00:00-04:00,2024-07-22,Johnson & Johnson seeks U.S. FDA approval of SPRAVATO® (esketamine) as the first and only monotherapy for adults with treatment-resistant depression,"Phase 4 SPRAVATO® monotherapy data shows rapid improvement in depressive symptoms at ~24 hours, sustained through at least 4 weeks Monotherapy submission builds on more than a decade of research, 31 clinical trials and more than five years of real-world use that reinforce the safety and efficacy of SPRAVATO® TITUSVILLE, N.J. , July 22, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO® (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD).",prnewswire.com,https://www.prnewswire.com/news-releases/johnson--johnson-seeks-us-fda-approval-of-spravato-esketamine-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression-302201474.html,https://images.financialmodelingprep.com/news/johnson-johnson-seeks-us-fda-approval-of-spravato-esketamine-20240722.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-22 09:30:00,2024-07-22T09:30:00-04:00,2024-07-22,Should You Pick Johnson & Johnson Stock At $155 After Q2 Beat?,"Johnson & Johnson (NYSE: JNJ) recently reported its Q2 results, with revenues aligning and earnings exceeding our estimates. The company reported revenue of $22.4 billion and adjusted earnings of $2.82 per share, compared to our estimates of $22.5 billion and $2.72, respectively.",forbes.com,https://www.forbes.com/sites/greatspeculations/2024/07/22/should-you-pick-johnson--johnson-stock-at-155-after-q2-beat/,https://images.financialmodelingprep.com/news/should-you-pick-johnson-johnson-stock-at-155-after-20240722.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-22 12:19:19,2024-07-22T12:19:19-04:00,2024-07-22,Johnson & Johnson: Seriously Undervalued At Peak Pessimism,"Johnson & Johnson, the pharmaceutical giant with a 3.21% dividend yield, released financial results for Q2 2024 that exceeded my expectations. Its oncology franchise revenue was $5.09 billion for the three months ended June 30, 2024, an increase of 15.7% year-on-year. For example, sales of Darzalex, an anticancer medication, were $2.88 billion in the second quarter of 2024, up 18.4% year-on-year.",seekingalpha.com,https://seekingalpha.com/article/4705518-johnson-and-johnson-seriously-undervalued-at-peak-pessimism,https://images.financialmodelingprep.com/news/johnson-johnson-seriously-undervalued-at-peak-pessimism-20240722.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-23 10:28:05,2024-07-23T10:28:05-04:00,2024-07-23,4 Positives For Johnson & Johnson,"Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase. Its market multiples indicate the possibility of some uptick, and there are dividends to consider too.",seekingalpha.com,https://seekingalpha.com/article/4705772-4-positives-for-johnson-and-johnson,https://images.financialmodelingprep.com/news/4-positives-for-johnson-johnson-20240723.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-24 10:01:17,2024-07-24T10:01:17-04:00,2024-07-24,Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know,"Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",zacks.com,https://www.zacks.com/stock/news/2307613/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-you-should-know?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|most_searched_stocks-2307613,https://images.financialmodelingprep.com/news/johnson-johnson-jnj-is-attracting-investor-attention-here-is-what-20240724.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-24 10:12:10,2024-07-24T10:12:10-04:00,2024-07-24,Grab These 5 Overlooked Dividend Aristocrats Before Wall Street Catches On,24/7 Insights The Dividend Aristocrats provide dependable passive income streams.,247wallst.com,https://247wallst.com/investing/2024/07/24/grab-these-5-overlooked-dividend-aristocrats-before-wall-street-catches-on/,https://images.financialmodelingprep.com/news/grab-these-5-overlooked-dividend-aristocrats-before-wall-street-20240724.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-25 07:45:00,2024-07-25T07:45:00-04:00,2024-07-25,3 Beaten-Down Value Stocks Poised for a Massive Comeback: July 2024,"There are deals to be found in the current market. If the goal is to buy low and sell high, then investors should find lots to like among value and blue-chip stocks that have been beaten down and whose share price has been in the red over the past year.",investorplace.com,https://investorplace.com/2024/07/3-beaten-down-value-stocks-poised-for-a-massive-comeback-july-2024/,https://images.financialmodelingprep.com/news/3-beatendown-value-stocks-poised-for-a-massive-comeback-20240725.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-25 12:05:47,2024-07-25T12:05:47-04:00,2024-07-25,How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?,"Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.",zacks.com,https://www.zacks.com/stock/news/2309193/how-should-you-play-j-j-jnj-stock-after-q2-earnings-beat?cid=CS-STOCKNEWSAPI-FT-analyst_blog|most_popular_stocks-2309193,https://images.financialmodelingprep.com/news/how-should-you-play-jj-jnj-stock-after-q2-20240725.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-26 07:05:00,2024-07-26T07:05:00-04:00,2024-07-26,Johnson & Johnson Receives Positive CHMP Opinion for Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH),"If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson's comprehensive PAH portfolio has the potential to cover all guideline-recommended treatment pathways BEERSE, BELGIUM, July 26, 2024 (GLOBE NEWSWIRE) --  Janssen-Cilag International NV, a Johnson & Johnson company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the Marketing Authorisation (MA) of Yuvanci®. Yuvanci® is a single tablet combination therapy of macitentan 10 mg and tadalafil 40 mg (M/T STCT) as a substitution therapy for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, who are already treated with the combination of macitentan and tadalafil given concurrently as separate tablets.1 PAH is a rare, progressive and life-threatening disease characterised by the constriction of small pulmonary arteries and elevated blood pressure (hypertension) in the pulmonary circulation that eventually leads to right heart failure and death.2 ,3 The 2022 European Society of Cardiology/European Respiratory Society (ESC/ERS) pulmonary hypertension (PH) guidelines have strengthened recommendations on initial double combination therapy with macitentan and tadalafil for PAH patients without cardiopulmonary comorbidities.4 However, this requires patients to take multiple pills as no single tablet that targets two or more PAH-specific pathways is available for these patients in Europe.",globenewswire.com,https://www.globenewswire.com/news-release/2024/07/26/2919477/0/en/Johnson-Johnson-Receives-Positive-CHMP-Opinion-for-Yuvanci-Single-Tablet-Combination-Therapy-STCT-of-Macitentan-and-Tadalafil-for-Treatment-of-Patients-with-Pulmonary-Arterial-Hype.html,https://images.financialmodelingprep.com/news/johnson-johnson-receives-positive-chmp-opinion-for-yuvanci-single-20240726.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-26 09:05:00,2024-07-26T09:05:00-04:00,2024-07-26,FINAL DEADLINE: Ovarian Cancer Victims Have Until 5pm ET Today to Vote on Approximately $8 Billion J&J Talc Compensation Plan,"NEW YORK--(BUSINESS WIRE)--Today at 5pm ET is the final deadline for tens of thousands of ovarian cancer victims or their representatives to vote on the approximately $8 billion Johnson & Johnson (“J&J”) (NYSE: JNJ) talcum powder settlement, leaving claimants just hours to act. Talc claimants can vote on the plan at www.OfficialTalcClaims.com or by calling 1-888-431-4056. The approximately $8 billion plan, which has a net present value of $6.475 billion, will compensate current and futu.",businesswire.com,https://www.businesswire.com/news/home/20240726806059/en/FINAL-DEADLINE-Ovarian-Cancer-Victims-Have-Until-5pm-ET-Today-to-Vote-on-Approximately-8-Billion-JJ-Talc-Compensation-Plan/,https://images.financialmodelingprep.com/news/final-deadline-ovarian-cancer-victims-have-until-5pm-et-20240726.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-26 14:00:22,2024-07-26T14:00:22-04:00,2024-07-26,Top 10 Dividend Stocks For A Recession-Focused Portfolio In 2024,"Preparing for a recession and the next stock market decline is important as it can help you to significantly reduce the volatility of your investment portfolio. In this article, I have selected 10 companies which are particularly suitable for such a recession-proof portfolio, especially due to the companies' ability to pay sustainable dividends. All of the selected companies have a robust business model, strong competitive advantages, an excellent competitive position, and are financially healthy.",seekingalpha.com,https://seekingalpha.com/article/4707236-top-10-dividend-stocks-for-a-recession-focused-portfolio-in-2024,https://images.financialmodelingprep.com/news/top-10-dividend-stocks-for-a-recessionfocused-portfolio-in-20240726.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-27 06:35:00,2024-07-27T06:35:00-04:00,2024-07-27,Could Johnson & Johnson's Troubles With Talc Lawsuits Finally Be Coming to an End?,"Johnson & Johnson is attempting to resolve talc lawsuits through bankruptcy for a third time. This time around, it's letting claimants vote on its proposed settlement.",fool.com,https://www.fool.com/investing/2024/07/27/could-johnson-johnsons-troubles-with-talc-lawsuits/,https://images.financialmodelingprep.com/news/could-johnson-johnsons-troubles-with-talc-lawsuits-finally-be-20240727.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-29 13:37:34,2024-07-29T13:37:34-04:00,2024-07-29,Pharma companies less concerned after hearing from US on negotiated prices for Medicare,Four pharmaceutical companies involved in the first U.S. negotiations over prices for the Medicare program said they do not expect a significant impact on their businesses after seeing confidential suggested prices from the government for their drugs that will take effect in 2026.,reuters.com,https://www.reuters.com/business/healthcare-pharmaceuticals/pharma-companies-less-concerned-after-hearing-us-negotiated-prices-medicare-2024-07-29/,https://images.financialmodelingprep.com/news/pharma-companies-less-concerned-after-hearing-from-us-on-20240729.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-30 07:08:26,2024-07-30T07:08:26-04:00,2024-07-30,Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms,"As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the pandemic, is now breaking out of a multi-year consolidation phase.",marketbeat.com,https://www.marketbeat.com/stock-ideas/top-2-cheap-healthcare-stocks-to-buy-as-sector-outperforms/,https://images.financialmodelingprep.com/news/top-2-cheap-healthcare-stocks-to-buy-as-sector-20240730.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-30 12:35:39,2024-07-30T12:35:39-04:00,2024-07-30,Q3's Rising Stars: 3 Dow Stocks for Your Must-Watch List,"The Dow Jones Industrial Average is a laggard in 2024. While other indices roared higher over the first half of the year, the venerable Dow gained only about half of its peers.",investorplace.com,https://investorplace.com/2024/07/q3s-rising-stars-3-dow-stocks-for-your-must-watch-list/,https://images.financialmodelingprep.com/news/q3s-rising-stars-3-dow-stocks-for-your-mustwatch-20240730.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-30 18:42:00,2024-07-30T18:42:00-04:00,2024-07-30,DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible,"Findings from first-ever quadruplet therapy study with subcutaneous DARZALEX FASPRO® showed 60 percent reduction in risk of disease progression or death New regimen solidifies DARZALEX FASPRO ®  as a foundational frontline therapy in multiple myeloma with potential to significantly delay disease progression HORSHAM, Pa. , July 30, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) announced today that the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for induction and consolidation in patients with newly diagnosed multiple myeloma (NDMM) who are eligible for an autologous stem cell transplant (ASCT).1 Patients will have the opportunity to receive this DARZALEX FASPRO ®-based quadruplet therapy at initial diagnosis, providing them with a new treatment that may significantly improve outcomes.",prnewswire.com,https://www.prnewswire.com/news-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-us-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible-302210443.html,https://images.financialmodelingprep.com/news/darzalex-faspro-daratumumab-and-hyaluronidasefihjbased-quadruplet-regimen-approved-in-20240730.jpg
JNJ,2024-07-17,2024-07-10,2024-07-31,JNJ,,2024-07-31 14:30:32,2024-07-31T14:30:32-04:00,2024-07-31,7 Leading MedTech Stocks for Next-Gen Health Solutions,"While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.",investorplace.com,https://investorplace.com/2024/07/7-leading-medtech-stocks-for-next-gen-health-solutions/,https://images.financialmodelingprep.com/news/7-leading-medtech-stocks-for-nextgen-health-solutions-20240731.jpg
